# Retatrutide References: Cited Clinical Trials and Research | Retatrutide Chemical

> Full citation list for all retatrutide research cited on this site — Phase 2 trials, Phase 1b PK study, cryo-EM structure, MASLD substudy, TRIUMPH Phase 3. PubMed/DOI indexed.

Every claim on this site traces to a numbered entry here.

## Primary trial evidence

The 15 cited sources below cover the Phase 1b pharmacokinetic study, Phase 2 obesity and T2D RCTs, MASLD substudy, structural biology, comparative reviews, and Phase 3 program publications. Each citation includes DOI or PubMed URL.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss (review). 2024. https://pubmed.ncbi.nlm.nih.gov/39305981/
[8] Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT06662383
[9] et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. https://pubmed.ncbi.nlm.nih.gov/39724554/
[10] et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide. Nephrol Dial Transplant. 2025. https://pubmed.ncbi.nlm.nih.gov/41160422/
[11] Abulehia A, et al. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2026. https://doi.org/10.1002/edm2.70187
[12] et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/40916752/
[13] et al. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, and the Path Forward. Cureus. 2026. https://pubmed.ncbi.nlm.nih.gov/41909366/
[14] Chan ZH, et al. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. Cardiology in Review. 2026. https://doi.org/10.1097/CRD.0000000000001209
[15] Bhat S, et al. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World J Cardiol. 2025;17(8):107991. https://doi.org/10.4330/wjc.v17.i8.107991

---

A cartographic field digest of the published retatrutide trial record — each finding plotted to its study, the Phase 3 frontier marked open, and nothing here prescribed, dispensed, or sold.